An open label, single arm, phase Ib dose finding study of i.v. panobinostat (LBH589) with docetaxel and prednisone in patients with hormone refractory prostate cancer.

Trial Profile

An open label, single arm, phase Ib dose finding study of i.v. panobinostat (LBH589) with docetaxel and prednisone in patients with hormone refractory prostate cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 16 May 2012

At a glance

  • Drugs Docetaxel; Panobinostat; Prednisone
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 16 May 2012 Actual end date changed from Han 2012 to Dec 2011 as reported by ClinicalTrials.gov.
    • 30 Apr 2012 Actual end date (Jan 2012) added as reported by ClinicalTrials.gov.
    • 30 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top